Article

Difluprednate Shows Itself Effective for Intermediate Uveitis Treatment

Author(s):

Difluprednate, a steroid stronger than prednisolone, was recently tested for treatment of macular edema and vitritis in cases of posterior/intermediate uveitis, and its impact was noticeable.

Difluprednate, a steroid stronger than prednisolone, was recently tested for treatment of macular edema and vitritis in cases of posterior/intermediate uveitis. Difluprednate, in solution form, is typically used in cases of inflammation following ocular surgeries.

The study, presented at this week's American Academy of Ophthalmology 2016 Meeting, included 54 eyes in 38 patients, all with vitreous haze score (VHS) greater than or equal to 2. The primary outcome was a decrease in those scores, and secondarily, the researchers were looking for any difference in visual acuity or central foveal thickness.

The topical steroid was applied twice a day in a 0.05% eye drop solution, and at a mean distance of 34 weeks, it displayed its efficacy. Average VHS score decreased from 2.18 (±0.39) down to 0.11 (±0.21). Noticeable differences were also observed in central foveal thickness, in addition to a modest increase in visual acuity.

No major adverse systemic or ocular side effects were reported in the studio, though the potential risks of longterm topical steroid use are well documented. With all defined outcomes met, the study authors conclude that their work “suggests that topical difluprednate is effective for the treatment of vitritis and macular edema in patients with posterior/intermediate uveitis.”

Related Coverage

Assessing Rates of Noninfectious Vitritis after Intravitreal Injection of Anti-VEGF Agents

Amsler vs. Casa: Which Test Better Detects Early Wet AMD?

Does Dry Eye Disease Hinder Sleep Quality and Mood?

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Gideon Hirschfield, FRCP, PhD | Credit: UHN Foundation
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
Country-Level Socioeconomic Status, Healthcare Impact AKI Outcomes in Cirrhosis
© 2024 MJH Life Sciences

All rights reserved.